Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik sold 36,979 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $37.30, for a total value of $1,379,316.70. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Karyopharm Therapeutics (NASDAQ:KPTI) traded down 0.19% on Wednesday, hitting $37.31. 180,133 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 1-year low of $15.50 and a 1-year high of $47.98. The stock has a 50-day moving average of $37.73 and a 200-day moving average of $34.24. The company’s market cap is $1.219 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, August 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.52. Analysts expect that Karyopharm Therapeutics will post $-2.19 EPS for the current fiscal year.

A number of analysts have recently weighed in on KPTI shares. Analysts at Leerink Swann cut their price target on shares of Karyopharm Therapeutics from $63.00 to $60.00 in a research note on Friday, August 8th. Analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One investment analyst has rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $52.67.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.